By Scott Meacham Copyright © 2016, The Oklahoma Publishing Company The “exit” is the holy grail for any startup, especially for a biotechnology company. Millions of dollars and years of time go into the development of a new therapeutic. If it works, a pharmaceutical company will take a new drug to market; if not, theRead more
0%
